Todd Gould
Professor of Psychiatry and Director of the Program in Neuroscience at the University of Maryland School of Medicine
Data updated
Research Footprint
Todd Gould appears in 7 tracked papers (2016–2024), most studied alongside Ketamine and Esketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Healthy Volunteers.
Most-cited paper: NMDAR inhibition-independent antidepressant actions of ketamine metabolites (1590 citations).
Frequent co-authors: Carlos Zarate, Mark Andrew Frye and Michael Grunebaum.
Background & Research
Todd Denton Gould, MD, is an American psychiatrist and academic researcher at the University of Maryland School of Medicine. He earned his MD from the University of Virginia and completed fellowship training at the National Institute of Mental Health Laboratory of Molecular Pathophysiology and Experimental Therapeutics. His research focuses on the biology of mood disorders, rapid-acting antidepressants, and translational animal models that bridge basic neuroscience and clinical psychiatry.
Key Impact
A leading translational psychiatry researcher whose work has helped shape modern understanding of ketamine and rapid-acting antidepressant mechanisms.
Collaboration Network
8 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Todd Gould is associated with.
University of Maryland School of Medicine
The University of Maryland School of Medicine (UMSOM), founded in 1807 and located in Baltimore, Maryland, is the medical school of the University of Maryland, Baltimore. It provides medical education, biomedical research, and clinical patient care and is affiliated with the University of Maryland Medical Center.
View stakeholder →National Institute of Mental Health (NIMH)
governmentU.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
View stakeholder →